Analytical Data
-
基因名
SGCa
- Application
-
别名
SGCa；ADL；DAG2；Alpha-sarcoglycan
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16586
-
表达区间
1-387aa
-
氨基酸序列
MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPE HVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGL QVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLP STPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKEGVYIKV GSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLV DKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLV ALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAAS REVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH
-
分子量
69 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCa, or sarcoglycan alpha, is a crucial component of the dystrophin-glycoprotein complex found in skeletal and cardiac muscle cells, playing a vital role in maintaining cellular integrity and function. Mutations in the SGCA gene are associated with a group of muscular dystrophies, particularly limb-girdle muscular dystrophy type 2D (LGMD2D), which leads to progressive muscle weakness and degeneration. The study of SGCa recombinant proteins has gained significant attention as researchers strive to understand the molecular mechanisms involved in muscle cell stability and pathology. By producing and characterizing these recombinant proteins, scientists aim to elucidate the structure-function relationships of SGCa, explore potential therapeutic avenues, and assess their role in muscle regeneration and repair. Furthermore, the development of animal models expressing mutated forms of SGCa allows for in vivo studies, fostering insights into disease progression and potential interventions. As advancements in gene editing and protein engineering continue, the exploration of SGCa recombinant proteins presents opportunities for innovative treatments that could mitigate the effects of muscular dystrophies and improve the quality of life for affected individuals. Overall, the ongoing research on SGCa and its recombinant forms represents a promising frontier in understanding muscular dystrophies and developing targeted therapies.
